Arete Wealth Advisors’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$723K Buy
51,765
+13,711
+36% +$192K 0.05% 244
2025
Q4
$548K Buy
38,054
+1,801
+5% +$27.1K 0.03% 412
2025
Q3
$577K Buy
+36,253
New +$597K 0.04% 394
2019
Q2
Sell
-471,136
Closed -$10.2M 394
2019
Q1
$10.2M Buy
471,136
+442,935
+1,571% +$9.43M 2.12% 5
2018
Q4
$624K Buy
+28,201
New +$600K 0.15% 167

Other funds holding BTAL

Arete Wealth Advisors's BTAL Position: Q1 2026 in Review

Arete Wealth Advisors increased its AGF US Market Neutral Anti-Beta Fund (BTAL) stake by 36% in Q1 2026, buying an estimated $192K and bringing the position to 51,765 shares worth $723K. The position accounts for 0.05% of the portfolio, ranked #244.

Arete Wealth Advisors first reported a position in BTAL in Q4 2018 and has held it in 5 quarters since. The position peaked at $10.2M in Q1 2019. 87 funds tracked by Wall St. Rank hold BTAL as of Q1 2026.

  • Arete Wealth Advisors held 51,765 shares of AGF US Market Neutral Anti-Beta Fund worth $723K as of Q1 2026.
  • Arete Wealth Advisors bought 13,711 AGF US Market Neutral Anti-Beta Fund shares in Q1 2026, an estimated $192K.
  • AGF US Market Neutral Anti-Beta Fund made up 0.05% of Arete Wealth Advisors's portfolio in Q1 2026, its #244 holding.
  • Arete Wealth Advisors first reported a position in AGF US Market Neutral Anti-Beta Fund in Q4 2018 and has held it in 5 quarters since.
  • Arete Wealth Advisors's AGF US Market Neutral Anti-Beta Fund position peaked at $10.2M in Q1 2019.
  • 87 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q1 2026.

Based on Arete Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.